Mazdutide
$77.99
Mazdutide (IBI362/LY3305677) is an investigational synthetic peptide studied for its activity at both GLP-1 and glucagon receptors. It has been evaluated in clinical research related to metabolic and endocrine signaling pathways involved in appetite regulation, energy balance, and glucose control mechanisms.
Usage Disclaimer: Research Use Only. This product is intended strictly for laboratory research and in-vitro studies. It is not for human or animal consumption, medical use, or diagnostic purposes. Any unauthorized use of this product is strictly prohibited.
FDA Compliance: FDA Notice. The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Research Studies
GLORY-1 Phase 3 Trial - NEJM (2025)
610 Chinese adults with obesity/overweight | 48 weeks | 4mg and 6mg doses
First Phase 3 weight management trial showing clinically meaningful weight reductions with once-weekly mazdutide. Both doses achieved significant weight loss vs placebo with favorable safety profile.
GLORY-2 Phase 3 Trial (2025)
462 Chinese adults with obesity (BMI ≥30) | 60 weeks | 9mg dose
High-dose 9mg mazdutide achieved 20.1% weight loss in non-diabetic participants vs 2.8% placebo. 48.7% achieved ≥20% weight reduction. No plateau observed through week 60.
DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide (2025)
349 Chinese adults with T2D and obesity | 32 weeks | Mazdutide vs Semaglutide
Mazdutide showed superiority over semaglutide on primary endpoint - 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). Mean HbA1c reduction -2.03% vs -1.84%.
Pair your peptide order with bacteriostatic water for proper reconstitution and storage. Adding it now ensures you have everything you need when your order arrives.
Avoid delays and complete your setup in one shipment.
